Luciano Costa, MD, PhD, Associate Director for Clinical Research at the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, Birmingham, AL, discusses the CARTITUDE-1 study of ciltracabtagene autoleucel in patiets with relapsed/refractory multiple myeloma. This study used a contemporary US-based dataset of patients with multiple myeloma refractory to treatment with anti-CD38 monoclonal antibodies to select patients who would meet eligibility for inclusion. According to Dr Costa, patients who received ciltracabtagene autoleucel experienced higher response rates and improved progression-free and overall survival compared with patients who received conventional treatment.